Skip to content
buyWeak

Jill Ackerman Jones bought $50k of PRFT

director at PERFICIENT INC. 817 shares at an average of $61.15, traded Nov 10, 2023, filed Nov 14, 2023.

Conviction score
28
Value
$50k
817 shares
Holdings after
3,500
+30% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $50k at market
    +7
  • Relative to holdings
    Holdings up 30%
    +6
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001085869-23-000192, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 10, 2023POpen-market purchase
Common Stock
+817$61.15$50k3,500Nov 14, 2023
Nov 10, 2023AGrant or award
Common Stock
+811$61.53$50k4,311Nov 14, 2023

Related signals

Other insiders at PERFICIENT INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
36Weak
PRFTsell 4
PERFICIENT INC
Susan L. Adomite
SVP, Controller & PAO
$34k
490 shares
-3%
64Notable
PRFTsell 4
PERFICIENT INC
Thomas J. Hogan
President and CEO
$914k
13,458 shares
-7%
53Moderate
PRFTsell 4
PERFICIENT INC
Paul E Martin
Chief Financial Officer
$407k
5,993 shares
-3%
38Weak
PRFTsell 4
PERFICIENT INC
Kevin Thomas Sheen
Senior Vice President
$71k
1,022 shares
-4%
13Weak
PRFTsell 210b5-1
PERFICIENT INC
Thomas J. Hogan
President and CEO
$9,030
129 shares
-0%
41Moderate
PRFTsell 2
PERFICIENT INC
David S Lundeen
director
$255k
4,000 shares
-11%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.